Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference

Core Insights - Collegium Pharmaceutical, Inc. announced four poster presentations featuring real-world data on its ADHD product, Jornay PM, at the APSARD Annual Conference from January 15-18, 2026 [1][2] Group 1: Product Information - Jornay PM is a central nervous system stimulant indicated for the treatment of ADHD in individuals aged 6 years and older, utilizing a novel delayed-release extended-release delivery platform [1][11] - The poster presentations will cover various aspects of Jornay PM, including optimal dosing, risk-benefit evaluation compared to Concerta, changes in functioning, and effects on depression and anxiety severity in adults [3] Group 2: Company Strategy - Collegium is focused on enhancing clinical decision-making through sustained investment in real-world evidence generation, aiming to improve care for ADHD patients [2] - The company is building a diversified biopharmaceutical portfolio, with ADHD as a key growth driver, and is committed to disciplined capital deployment [12]